Recent insights into the mechanism of action of glatiramer acetate

Mrinalini Kala, Augusto Miravalle, Timothy Vollmer

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Glatiramer acetate (GA, Copaxone®, co-polymer 1) is an immunomodulatory therapy approved in 1996 by the United States Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis. GA has a good safety profile, moderate efficacy, and a unique mode of action. Recent evidence in an animal model of MS, experimental autoimmune encephalomyelitis (EAE), suggests that GA effects on NK cells and B cells may contribute to therapeutic efficacy. We review the mechanism of action of GA, with particular focus on recent data suggesting a role for regulatory B cells.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - Jun 2011


  • B cells
  • Glatiramer acetate
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Recent insights into the mechanism of action of glatiramer acetate'. Together they form a unique fingerprint.

Cite this